Market Forecast News: Biopharmaceutical CDMO to Hit $34.15B by 2030

Global biopharmaceutical contract manufacturing market valued at $20.51B in 2024, reached $22.40B in 2025, and is projected to grow at a robust 8.8% CAGR
In the near future, the biotechnology contract manufacturing industry is poised for unprecedented growth and innovation. With a burgeoning demand for personalized medicines, advanced biologics, and cutting-edge therapies, contract manufacturing organizations (CMOs) will play a pivotal role in expediting drug development and production. This industry's landscape will witness the convergence of state-of-the-art bioprocessing technologies, such as continuous manufacturing and gene editing, allowing for more efficient and scalable production of biopharmaceuticals. Furthermore, the rise of sustainable and eco-friendly bioprocessing techniques will align with global environmental concerns. Collaborations between CMOs, biotech startups, and pharmaceutical giants will become increasingly common, fostering a dynamic ecosystem that accelerates the delivery of life-saving therapies to patients worldwide. As regulatory frameworks adapt to accommodate these advancements, the biotechnology contract manufacturing sector is on the cusp of a transformative era, revolutionizing healthcare and shaping the future of medicine.

Biotechnology Contract Manufacturing Market [https://www.marketsandmarkets.com/Market-Reports/biotechnology-ccontract-manufacturing-market-163964739.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] in terms of revenue was estimated to be worth $16.6 billion in 2023 and is poised to reach $24.8 billion by 2028, growing at a CAGR of 8.3% from 2023 to 2028 according to a new report by MarketsandMarkets Trademark . The growth of this market is driven by the rising demand for biologics and biosimilars, increasing outsourcing of biologics manufacturing among biopharmaceutical companies, growing focus on personalized medicine, increasing collaborations between pharmaceutical companies and biologics contract manufacturers, and advancements in manufacturing technologies. Additionally, the rising demand for cell & gene therapies and the expansion of biologics manufacturing capacities by CMOs will provide growth opportunities in the biotechnology contract manufacturing market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163964739 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163964739&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Biotechnology Contract Manufacturing Market Scope:

Report Coverage

Details

Market Revenue in 2023

$16.6 billion

Estimated Value by 2028

$24.8 billion

Growth Rate

Poised to grow at a CAGR of 8.3%

Market Size Available for

2021-2028

Forecast Period

2023-2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Service, Type, Source, Scale of Operation, Molecule Type, Therapeutic Area, and Region

Geographies Covered

North America, Europe, Asia Pacific, Latin America (LATAM), and Middle East and Africa (MEA)

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Rising demand for cell therapies and gene therapies

Key Market Drivers

Increasing biologics manufacturing outsourcing trend among biopharmaceutical companies

The monoclonal antibody segment accounted for the largest share by molecule type in the biotechnology contract manufacturing market in 2022.

By molecule type, the biotechnology contract manufacturing market has been further categorized as monoclonal antibodies, cell therapy & gene therapy, antibody-drug conjugates, vaccines, therapeutic peptides & proteins, and other molecule types. The monoclonal antibodies segment held the largest share of the global biotechnology contract manufacturing market in 2022. This can be attributed to the growing demand for targeted therapies in the treatment of chronic diseases, increasing government initiatives for the development of monoclonal antibody drugs, and the growing number of mAb product candidates currently in development.

The mammalian expression segment accounted for the largest share of the biotechnology contract manufacturing market by source in 2022.

Based on the source, the global biotechnology contract manufacturing market has been segmented into mammalian expressions and non-mammalian expressions. The mammalian expression segment held the largest market share in 2022. The large share of this segment can be attributed to the high sensitivity of this system, its wide usage in the manufacturing of biopharmaceuticals, the growing number of approved biologics based on mammalian expression systems, and the expansion of mammalian-based cell culture capacity by CMOs.

North America region accounted for the dominant share of the biotechnology contract manufacturing market in 2022.

The biotechnology contract manufacturing market in North America has experienced significant growth in recent years. The strong pharmaceutical and biotech industry, the presence of a well-established pharmaceutical industry, the rising demand for biosimilars and biologics, and the increasing outsourcing of manufacturing services by pharmaceutical & biopharmaceutical companies contribute to the growth of the biotechnology contract manufacturing market in the North American region. Additionally, the presence of highly advanced manufacturing technologies makes this region an attractive market for contract manufacturing organizations (CMOs).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=163964739 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163964739&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Biotechnology Contract Manufacturing Market Dynamics:

Drivers:

* Rising demand for biologics and biosimilars
* Increasing outsourcing of biologics manufacturing among biopharmaceutical companies
* Growing focus on personalized medicine
* Increasing collaborations between pharmaceutical companies and biologics CMOs
* Advancements in manufacturing technologies

Restraints:

* Intellectual property rights issues

Opportunities:

* Rising demand for cell and gene therapies
* Significant growth opportunities offered by emerging countries
* Expansion of biologics manufacturing capacities by CMOs
* Strong emphasis on drug development

Challenge:

* Complying with regulatory reforms

Key Market Players:

Key players in the biotechnology contract manufacturing market include Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), WuXi Biologics (China), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holdings Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC Inc. (Japan), Merck KGaA (Germany), JSR Corporation (Japan) and among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163964739 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163964739&utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=market-forecast-news-biopharmaceutical-cdmo-to-hit-3415b-by-2030]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/biotechnology-ccontract-manufacturing-market-163964739.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.